TVTX
Travere Therapeutics Inc
1 day chart
About TVTX
Travere Therapeutics Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and delivering therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products are Thiola and Thiola EC (tiopronin tablets) used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The Company has received approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II) and is a non-immunosuppressive therapy approved for the treatment of this condition. FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA). Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN in the United States and Europe.
Buy US stocks in Australia starting with TVTX. Open an account and start investing today!
$966.14M
-
0.00%
17.34M
$7.80
$7.00
$7.55
$26.55
$12.58
TVTX FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in TVTX
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.